| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d33087dfb06f23a561b692aecc073feb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_397384a6d230e34cf9e18e9c7d9b0a03 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-627
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-605
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A90-10 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate |
2013-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b4b82933a5e654ee8cfd175ff11b6f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c9d4c64ba4efe4b6855c7fd2a7ada9d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7351ddf252d8bc6ef8b4e50e57632fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c68576646fb36122ec2d142fd80af07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c383623644393e54bd9edfc5e75b9187 |
| publicationDate |
2018-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3417874-A1 |
| titleOfInvention |
Individualized vaccines for cancer |
| abstract |
The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020242766-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11545238-B2 |
| priorityDate |
2012-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |